NEOGENOMICS INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We operate an international network of laboratories. Our leases expire at various dates through 2041. We believe that these locations are sufficient to meet our needs at existing volume levels and, if needed, additional space will be available at a reasonable cost.
| Table of Contents | NEOGENOMICS, INC. |
|---|
We maintain laboratories at all of our facilities, as well as administrative offices at four of our locations. The following table summarizes our facilities by location and approximate square footage:
| Location | Square Footage |
|---|---|
| Durham, North Carolina | 187,700 |
| Fort Myers, Florida | 150,000 |
| Aliso Viejo, California | 112,700 |
| Carlsbad, California | 28,600 |
| Houston, Texas | 28,100 |
| San Diego, California | 25,400 |
| Cambridge, United Kingdom | 12,500 |
| Nashville, Tennessee | 7,800 |
| Tampa, Florida | 5,600 |
| Phoenix, Arizona | 4,700 |
| Atlanta, Georgia | 3,800 |
| Fresno, California | 2,600 |
| Chicago, Illinois | 2,200 |
Our Nashville, Tennessee; Tampa, Florida; Atlanta, Georgia; and Phoenix, Arizona locations support our Clinical Services segment exclusively. All other locations serve both segments of the business. For further financial information about our segments, please refer to Note 17. Segment Information, in the notes to our Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.